medwireNews: Early results from a phase 2a trial show that 12 weeks of treatment with the novel agent bexotegrast reduced type 1 collagen deposition in patients with idiopathic pulmonary fibrosis (IPF).
09-09-2024 | Idiopathic Pulmonary Fibrosis | News